Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561284 | 0.88 | HTT (0.64) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.88 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL15706894 | 0.85 | ALOX5 (0.47) | HTTSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL16684292 | 0.83 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8413415 | 0.83 | HTT (0.56) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8762477 | 0.83 | HTT (0.59) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL4162991 | 0.83 | NPC1 (0.69) | SMN1; SMN2KMT2AMAPTNPC1ALOX5 | |
| SCHEMBL3082334 | 0.81 | TSHR (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL16957610 | 0.81 | HTT (0.55) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL38446 | 0.81 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-6448442-B1 | X-RAY CONTRAST AGENTS; LOW VISCOSITY IODINATED ARYL COMPOUNDS | AMERSHAM HEALTH AS (NO) | 2002-09-10 | — | — | US | disclosed |
| US-6310243-B1 | BENZENE COMPOUNDS IN WHICH 3 NON-ADJACENT RING ATOMS ARE SUBSTITUTED WITH IODINE, 2 OF THE REMAINING RING ATOMS ARE AMIDE SUBSTITUTED WITH HYDROXY AND THE OTHER REMAINING RING ATOM IS A NON-AMIDE, HYDROXY-SUBSTITUTED NONIONIC MOIETY | NYCOMED IMAGING AS (NO) | 2001-10-30 | — | — | US | disclosed |
| CN-1069633-C | Iodo-substituted X-ray contrast agents | NYCOMED IMAGING AS (NO) | 2001-08-15 | — | — | CN | disclosed |
| US-5993780-A | A POLYIODOARYLALKYL ALCOHOL OR DERIVATIVE | NYCOMED IMAGING AS (NO) | 1999-11-30 | — | — | US | disclosed |
| EP-0782564-B1 | IODINATED X-RAY CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1999-09-01 | — | — | EP | disclosed |
| US-5882628-A | Contrast media | NYCOMED IMAGING AS (NO) | 1999-03-16 | — | — | US | disclosed |
| CN-1166826-A | Iodo-substituted X-ray contrast agents | NYCOMED IMAGING AS (NO) | 1997-12-03 | — | — | CN | disclosed |
| EP-0782564-A1 | IODINATED X-RAY CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009282-A1 | IODINATED X-RAY CONTRAST MEDIA | NYCOMED IMAGING A/S (NO) | 1996-03-28 | — | — | WO | disclosed |
| CN-1090572-A | \" new polyiodide, their preparation method and contain their contrast medium \ | GUERBET SA (FR) | 1994-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | HTT 2066/4885SMN1; SMN2 1569/4885GAA 2972/4885 |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | HTT 2869/4885SMN1; SMN2 3216/4885GAA 4216/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | HTT 1943/4885SMN1; SMN2 1527/4885GAA 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.